{"success":true,"data":{"pressRelease":{"id":"117160","rtpr_id":"nGNX6KqRnF","ticker":"OPRX","exchange":"NASDAQ","all_tickers":["OPRX"],"title":"OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance","author":"Globe Newswire","published_at":"2026-08-12T20:01:00.804Z","article_body":"–  Q2 revenue totals $20.5 million\n–  Q2 net loss and adjusted EBITDA of $(0.7) million and $4.9 million,\nrespectively\n–  Reaffirms fiscal year 2026 revenue guidance of $95 - $100 million and\nadjusted EBITDA guidance of $21 - $25 million\n–  Completed debt refinancing with $35 million traditional banking\nfacility, including $25 million term loan and $10 million undrawn revolver;\nrepaid $8.3 million of principal since inception\n\nWALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the\n“Company”) (Nasdaq: OPRX), a leading provider of healthcare technology\nsolutions helping life sciences companies reach and engage healthcare\nprofessionals (HCPs) and patients, today announced results for the three\nmonths ended June 30, 2026.\n\nFinancial Highlights\n* Revenue decreased 30% to $20.5 million in Q2 2026, compared to $29.2 million\nin Q2 2025.\n* GAAP net loss of $(0.7) million or $(0.04) per basic and diluted share in Q2\n2026, compared to GAAP net income of $1.5 million, or $0.08 per basic and\ndiluted share, in Q2 2025.\n* Non-GAAP net income of $3.1 million, or $0.16 per diluted share in Q2 2026,\ncompared to Non-GAAP net income of $3.7 million or $0.19 per diluted share, in\nQ2 2025. (See *Non-GAAP Measures below)\n* Adjusted EBITDA of $4.9 million in Q2 2026 compared to $5.8 million in Q2\n2025. (See *Non-GAAP Measures below)\n* Cash and cash equivalents of $24.1 million as of June 30, 2026 compared to\n$23.4 million as of December 31, 2025.\nStephen L. Silvestro, OptimizeRx CEO commented, “Second quarter revenue and\nadjusted EBITDA both exceeded consensus expectations, reflecting continued\nmargin expansion, disciplined execution, and resilience in our operating\nmodel. While year-over-year revenue declined and contracted revenue remains\nbelow prior-year levels, these trends are concentrated among a small number of\ncustomers, and we are encouraged by increased investment across other portions\nof our customer base. Our continued investment in platform capabilities,\nincluding recent product launches and expanded programmatic initiatives, is\nstrengthening customer engagement as we move into the 2027 planning cycle.\nDespite some variability in second-half timing and mix, our first-half\nperformance and commercial momentum give us confidence to reiterate full-year\n2026 guidance of $95 million to $100 million in revenue and $21 million to $25\nmillion in adjusted EBITDA. We also expanded the long-term opportunity for\nOptimizeRx through three platform advancements: DeepIntent became the first\nhealthcare demand-side platform (DSP) to integrate our authenticated\nelectronic health record (EHR) network, we launched our patent-pending Natural\nLanguage Audience Builder, and we introduced CopayCue, our next-generation\ncopay activation solution. These innovations strengthen our position in\nartificial intelligence (AI)-enabled audience intelligence, programmatic\npoint-of-care activation, and clinical workflow engagement while creating\nopportunities for recurring growth.\n\n“Finally, we continued to strengthen our balance sheet by paying down $5.3\nmillion of term loan principal during the quarter—$5.0 million ahead of\nschedule—and an additional $3.0 million subsequent to quarter-end. We\nbelieve our disciplined execution, expanding technology platform, improving\ncustomer engagement, and strong financial position leave us well positioned to\ncreate meaningful long-term shareholder value.”\n\n Rolling Twelve Months Ended \n June 30, \n Key Performance Indicators (KPIs)** 2026 2025 \n (in thousands, except percentages) \n Average revenue per top 20 pharmaceutical manufacturers $ 2,659 $ 3,095 \n Percent of total revenue attributable to top 20 pharmaceutical manufacturers 54 % 59 % \n Net revenue retention 90 % 121 % \n Revenue per average full-time employee $ 750 $ 767 \n \n\n2026 Financial Outlook\n\nThe Company is reiterating its fiscal year 2026 guidance, and expects revenue\nof $95 million to $100 million and adjusted EBITDA of $21 million to $25\nmillion.\n\nConference Call\n\n Date: Wednesday, August 12, 2026 \n Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) \n Toll Free: 1-877-407-9716 \n International: 1-201-493-6779 \n Conference ID: 13761843 \n Call Me : https://callme.viavid.com/viavid/?callme=true&passcode=13760191&h=true&info=company-email&r=true&B=6 \n Webcast : https://viavid.webcasts.com/starthere.jsp?ei=1770269&tp_key=7d483832d3 \n Webcast Replay : The archived webcast will be on the investor relations section of the OptimizeRx website. \n \n\nIndividual Meeting Invitation\n\nIn an effort to increase relations with institutional investors, OptimizeRx\nmanagement has dedicated time to hosting individual meetings with portfolio\nmanagers and analysts. If you are interested in scheduling a meeting with\nOptimizeRx management, please contact: adsilva@optimizerx.com or\ndfarrell@lifesciadvisors.com.\n\n*Non-GAAP Measures\n\nIn addition to the financial measures prepared in accordance with generally\naccepted accounting principles (GAAP), this earnings release also contains\nnon-GAAP financial measures. The reasons why we believe these measures provide\nuseful information to investors and, for historical periods, a reconciliation\nof these measures to the most directly comparable GAAP measures are included\nin the supplemental tables that follow.\n\nAlthough the Company provides guidance for adjusted EBITDA, a non-GAAP\nfinancial measure, it is not able to provide guidance to the most directly\ncomparable GAAP measure. Reconciliations for forward-looking figures would\nrequire unreasonable effort at this time because of the uncertainty and\nvariability of the nature and amount of certain components of various\nnecessary GAAP components, including, for example, those related to\ncompensation, acquisition expenses, other income, amortization or others that\nmay arise during the year, and the Company’s management believes such\nreconciliations would imply a degree of precision that would be confusing or\nmisleading to investors. For the same reasons, the Company is unable to\naddress the probable significance of the unavailable information.\n\n**Definition of Key Performance Indicators\n\nTop 20 pharmaceutical manufacturers: We have updated the definition of “top\n20 pharmaceutical manufacturers” in our key performance indicators to be\nbased upon Fierce Pharma’s most updated list of “The top 20 pharma\ncompanies by 2025 revenue”. We previously used “The top 20 pharma\ncompanies by 2024 revenue”. As a result of this change, prior periods have\nbeen restated for comparative purposes.\n\nNet revenue retention: Net revenue retention is a comparison of revenue\ngenerated from all clients in the previous period to total revenue generated\nfrom the same clients in the following year (i.e., excludes new client\nrelationships for the most recent year).\n\nRevenue per average full-time employee: We define revenue per average\nfull-time employee (FTE) as total revenue over the last 12 months (LTM)\ndivided by the average number of employees over the LTM, which is calculated\nby taking our total number of FTEs at the end of the prior year period by our\ntotal FTE headcount at the end of the most recent period.\n\nAbout OptimizeRx\n\nOptimizeRx is a leading healthcare technology company that’s redefining how\nlife science brands connect with patients and healthcare providers. Our\nplatform combines innovative AI-driven tools like the Dynamic Audience\nActivation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver\ntimely, relevant, and hyper-local engagement. By bridging the gap between HCP\nand direct-to-consumer (DTC) strategies, we empower brands to create\nsynchronized marketing solutions that drive faster treatment decisions and\nimproved patient outcomes.\n\nOur commitment to privacy-safe, patient-centric technology ensures that every\ninteraction is designed to make a meaningful impact, delivering life-changing\ntherapies to the right patients at the right time. Headquartered in Waltham,\nMassachusetts, OptimizeRx partners with some of the world’s leading\npharmaceutical and life sciences companies to transform the healthcare\nlandscape and create a healthier future for all.\n\nFor more information, follow the Company on X, LinkedIn or\nvisit www.optimizerx.com. \n\nImportant Cautions Regarding Forward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Words such as\n“anticipates”, “believes”, “estimates”, “expects”,\n“forecasts”, “intends”, “plans”, “projects”, “targets”,\n“designed”, “could”, “may”, “should”, “will” or other\nsimilar words and expressions are intended to identify these forward-looking\nstatements. All statements that reflect the Company’s expectations,\nassumptions, projections, beliefs or opinions about the future, other than\nstatements of historical fact, are forward-looking statements, including,\nwithout limitation, statements relating to the Company’s future performance,\nexpected revenues, expected adjusted EBITDA, AI-enabled audience intelligence,\nprogrammatic point-of-care activation, clinical workflow engagement creating\nopportunities for recurring growth, the Company's disciplined execution,\nexpanding technology platform, increased customer investment, and strong\nfinancial position leaving the Company to be well-positioned to create\nmeaningful long-term shareholder value, and other statements relating to\nfuture performance, plans, and expectations. These forward-looking statements\nare based on the Company’s current expectations and involve assumptions\nregarding the Company’s business, the economy, and other future conditions\nthat may never materialize or may prove to be incorrect. Forward-looking\nstatements are inherently subject to risks and uncertainties, some of which\ncannot be predicted, or quantified. Actual results and the timing of events\ncould differ materially from those anticipated in such forward-looking\nstatements as a result of various risks and uncertainties including, but not\nlimited to, the effect of government regulation, seasonal trends, dependence\non a concentrated group of customers, cybersecurity incidents that could\ndisrupt operations, the ability to keep pace with growing and evolving\ntechnology, the ability to maintain contracts with electronic prescription\nplatforms and electronic health records networks, competition, and other\nfactors discussed in the Company’s Annual Report on Form 10-K for the fiscal\nyear ended December 31, 2025, its subsequent Quarterly Reports on Form 10-Q,\nand in other filings the Company has made and may make with the Securities and\nExchange Commission in the future. One should not place undue reliance on\nthese forward-looking statements, which speak only as of the date on which\nthey were made. The Company undertakes no obligation to update such statements\nto reflect events that occur or circumstances that exist after the date on\nwhich they were made, except as may be required by law.\n\nOptimizeRx Contact\nAndy D’Silva, Chief Business Officer\nadsilva@optimizerx.com\n\nInvestor Relations Contact\nDouglas Farrell\nLifeSci Advisors, LLC\ndfarrell@lifesciadvisors.com\n\n OPTIMIZERX CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) \n \n June 30, December 31, \n 2026 2025 \n ASSETS (unaudited) \n Current assets \n Cash and cash equivalents $ 24,096 $ 23,365 \n Accounts receivable, net of allowance for credit losses of $260 and $260 at June 30, 2026 and December 31, 2025, respectively 24,796 37,752 \n Taxes receivable 2,328 752 \n Prepaid expenses and other 2,926 2,846 \n Total current assets 54,146 64,715 \n Property and equipment, net 122 106 \n Other assets \n Goodwill 70,869 70,869 \n Patent rights, net 4,267 4,586 \n Technology assets, net 6,281 6,870 \n Tradename and customer relationships, net 28,162 29,340 \n Operating lease right of use assets 452 404 \n Security deposits and other assets 18 28 \n Total other assets 110,049 112,097 \n TOTAL ASSETS $ 164,317 $ 176,918 \n \n LIABILITIES AND STOCKHOLDERS’ EQUITY \n Current liabilities \n Current portion of long-term debt $ 1,250 $ 4,255 \n Accounts payable 1,323 1,636 \n Accrued expenses 5,389 11,591 \n Revenue share payable 813 3,086 \n Current portion of lease liabilities 227 193 \n Deferred revenue 709 503 \n Total current liabilities 9,711 21,264 \n Non-current liabilities \n Long-term debt, net 17,757 21,421 \n Lease liabilities, net of current portion 246 234 \n Deferred tax liabilities, net 5,521 5,705 \n Total liabilities 33,235 48,624 \n Commitments and contingencies \n Stockholders’ equity \n Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding at June 30, 2026 or December 31, 2025 — — \n Common stock, $0.001 par value, 166,666,667 shares authorized, 20,574,233 and 20,500,986 shares issued at June 30, 2026 and December 31, 2025, respectively 21 20 \n Treasury stock, $0.001 par value, 1,741,397 shares held at June 30, 2026 and December 31, 2025. (2 ) (2 ) \n Additional paid-in-capital 211,486 207,512 \n Accumulated other comprehensive income (loss) 11 — \n Accumulated deficit (80,434 ) (79,236 ) \n Total stockholders’ equity 131,082 128,294 \n TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 164,317 $ 176,918 \n \n\n\n\n OPTIMIZERX CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) \n (in thousands, except share and per share data, unaudited) \n \n For the Three Months Ended For the Six Months Ended \n June 30, June 30, \n 2026 2025 2026 2025 \n \n Net revenue $ 20,504 $ 29,195 $ 40,348 $ 51,123 \n \n Expenses \n Cost of revenues, exclusive of depreciation and amortization presented separately below 4,816 10,560 9,728 19,144 \n Sales and marketing 5,528 5,865 10,257 10,850 \n General and administrative 3,702 3,909 7,215 8,466 \n Research and development 3,274 3,092 6,676 6,344 \n Stock-based compensation 2,208 1,488 4,036 3,046 \n Depreciation and amortization 1,064 1,074 2,128 2,168 \n Total expenses 20,592 25,988 40,040 50,018 \n Income from operations (88 ) 3,207 308 1,105 \n Other income (expense) \n Interest expense (1,127 ) (1,603 ) (2,282 ) (2,899 ) \n Other income 38 37 76 76 \n Interest income 81 90 158 177 \n Total other expenses, net (1,008 ) (1,476 ) (2,048 ) (2,646 ) \n Income (loss) before provision for income taxes (1,096 ) 1,731 (1,740 ) (1,541 ) \n Income tax benefit (expense) 393 (199 ) 542 874 \n Net income (loss) $ (703 ) $ 1,532 $ (1,198 ) $ (667 ) \n \n Other comprehensive income (loss), net of tax: \n Foreign currency translation adjustment 11 — 11 — \n Comprehensive income (loss) $ (692 ) $ 1,532 $ (1,187 ) $ (667 ) \n \n Weighted average number of shares outstanding – basic 18,785,596 18,510,834 18,773,638 18,490,931 \n Weighted average number of shares outstanding – diluted 18,785,596 19,015,496 18,773,638 18,490,931 \n Income (loss) per share – basic $ (0.04 ) $ 0.08 $ (0.06 ) $ (0.04 ) \n Income (loss) per share – diluted $ (0.04 ) $ 0.08 $ (0.06 ) $ (0.04 ) \n \n\n\n\n OPTIMIZERX CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands, unaudited) \n \n For the Six Months Ended June 30, \n 2026 2025 \n OPERATING ACTIVITIES: \n Net loss $ (1,198 ) $ (667 ) \n Adjustments to reconcile net loss to net cash provided by operating activities: \n Depreciation and amortization 2,128 2,168 \n Stock-based compensation 4,036 3,046 \n Amortization of debt issuance costs 635 611 \n Changes in: \n Accounts receivable 12,956 4,700 \n Prepaid expenses and other assets (81 ) (958 ) \n Accounts payable (313 ) (174 ) \n Revenue share payable (2,273 ) (2,462 ) \n Accrued expenses and other liabilities (6,190 ) 4,138 \n Operating lease liabilities (2 ) 9 \n Deferred tax liabilities (184 ) (1,033 ) \n Taxes receivable and payable (1,576 ) (964 ) \n Deferred revenue 206 11 \n NET CASH PROVIDED BY OPERATING ACTIVITIES 8,144 8,425 \n \n INVESTING ACTIVITIES: \n Purchase of property and equipment (56 ) (37 ) \n Capitalized software development costs — (91 ) \n NET CASH USED IN INVESTING ACTIVITIES (56 ) (128 ) \n \n FINANCING ACTIVITIES: \n Cash paid for employee withholding taxes related to the vesting of restricted stock units (63 ) (92 ) \n Proceeds from term loan, net of issuance costs 24,298 — \n Repayment of long-term debt (31,603 ) (5,000 ) \n NET CASH USED IN FINANCING ACTIVITIES (7,368 ) (5,092 ) \n EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH 11 \n EQUIVALENTS \n NET INCREASE IN CASH AND CASH EQUIVALENTS 731 3,205 \n CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD 23,365 13,380 \n CASH AND CASH EQUIVALENTS - END OF PERIOD $ 24,096 $ 16,585 \n \n SUPPLEMENTAL CASH FLOW INFORMATION: \n Cash paid for interest $ 1,566 $ 3,409 \n Cash paid for income taxes $ 1,223 $ 1,087 \n \n\nOPTIMIZERX CORPORATION\nRECONCILIATION of GAAP to NON-GAAP FINANCIAL MEASURES\n(in thousands, except share and per share data, unaudited)\n\nThis earnings release includes certain financial measures that are not\nprepared in accordance with generally accepted accounting principles (GAAP).\nThese non-GAAP financial measures are performance measures that are not\ndefined under GAAP and should be considered in addition to, and not as a\nsubstitute for, the most directly comparable GAAP measures. They may also not\nbe comparable to similarly titled measures reported by other companies.\nManagement believes that presenting these non-GAAP financial measures provides\nuseful supplemental information that facilitates comparison of the Company's\nhistorical operating results and trends, and offers transparency into how\nmanagement evaluates the business. Management uses these measures in making\nfinancial, operating and planning decisions and in evaluating the Company's\nperformance. Excluding items that management does not consider reflective of\nongoing operating results improves the comparability of year-over-year results\nand helps investors better understand the Company’s underlying performance.\nThese adjustments may include items such as asset impairment charges,\namortization, stock-based compensation, acquisition expenses, severance\nrelated to executive departures and reductions in force initiatives,\nshareholder activist related fees, CEO search fees, CMO search fees, other\nincome, estimated income tax impact from adjustments and other items that\nmanagement believes are not related to the Company’s ongoing performance.\n\n For the Three Months Ended June 30, For the Six Months Ended June 30, \n 2026 2025 2026 2025 \n Net income (loss) $ (703 ) $ 1,532 $ (1,198 ) $ (667 ) \n Depreciation and amortization 1,064 1,074 2,128 2,168 \n Stock-based compensation 2,208 1,488 4,036 3,046 \n Severance expenses 1,714 — 1,744 275 \n Shareholder activist related fees — — — 451 \n CEO search fees — — — 225 \n CMO search fees 40 — 40 — \n Other income (38 ) (37 ) (76 ) (76 ) \n Amortization of debt issuance costs 277 437 635 611 \n Estimated income tax impact from adjustments* (1,456 ) (819 ) (2,353 ) (1,853 ) \n Non-GAAP net income $ 3,106 $ 3,675 $ 4,956 $ 4,180 \n \n Non-GAAP net income per share \n Diluted $ 0.16 $ 0.19 $ 0.26 $ 0.22 \n Weighted average shares outstanding: \n Diluted 18,907,884 19,015,496 18,992,154 18,599,906 \n \n *Estimated income tax impact from adjustments - consists of current and deferred income tax expense commensurate with the level of adjusted income before income taxes and utilizes an estimated current, blended U.S. and state statutory annual tax rate of 27.6% for all fiscal periods of fiscal 2026 and fiscal 2025. This rate may be subject to change in the future, including as a result of changes in tax policy or tax strategy. \n \n\n\n\n For the Three Months Ended June 30, For the Six Months Ended June 30, \n 2026 2025 2026 2025 \n Net income (loss) $ (703 ) $ 1,532 $ (1,198 ) $ (667 ) \n Depreciation and amortization 1,064 1,074 2,128 2,168 \n Income tax (benefit) expense (393 ) 199 (542 ) (874 ) \n Stock-based compensation 2,208 1,488 4,036 3,046 \n Severance expenses 1,714 — 1,744 275 \n Shareholder activist related fees — — — 451 \n CEO search fees — — — 225 \n CMO search fees 40 — 40 — \n Other income (38 ) (37 ) (76 ) (76 ) \n Interest expense, net 1,046 1,513 2,124 2,722 \n Adjusted EBITDA $ 4,938 $ 5,769 $ 8,256 $ 7,270 \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/a0504bf7-72fc-4cd4-8489-a207313dbabd)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX6KqRnF","title":"OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance","author":"Globe Newswire","ticker":"OPRX","created":"2026-08-12T20:01:00.804Z","tickers":["OPRX"],"exchange":"NASDAQ","article_body":"–  Q2 revenue totals $20.5 million\n–  Q2 net loss and adjusted EBITDA of $(0.7) million and $4.9 million,\nrespectively\n–  Reaffirms fiscal year 2026 revenue guidance of $95 - $100 million and\nadjusted EBITDA guidance of $21 - $25 million\n–  Completed debt refinancing with $35 million traditional banking\nfacility, including $25 million term loan and $10 million undrawn revolver;\nrepaid $8.3 million of principal since inception\n\nWALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the\n“Company”) (Nasdaq: OPRX), a leading provider of healthcare technology\nsolutions helping life sciences companies reach and engage healthcare\nprofessionals (HCPs) and patients, today announced results for the three\nmonths ended June 30, 2026.\n\nFinancial Highlights\n* Revenue decreased 30% to $20.5 million in Q2 2026, compared to $29.2 million\nin Q2 2025.\n* GAAP net loss of $(0.7) million or $(0.04) per basic and diluted share in Q2\n2026, compared to GAAP net income of $1.5 million, or $0.08 per basic and\ndiluted share, in Q2 2025.\n* Non-GAAP net income of $3.1 million, or $0.16 per diluted share in Q2 2026,\ncompared to Non-GAAP net income of $3.7 million or $0.19 per diluted share, in\nQ2 2025. (See *Non-GAAP Measures below)\n* Adjusted EBITDA of $4.9 million in Q2 2026 compared to $5.8 million in Q2\n2025. (See *Non-GAAP Measures below)\n* Cash and cash equivalents of $24.1 million as of June 30, 2026 compared to\n$23.4 million as of December 31, 2025.\nStephen L. Silvestro, OptimizeRx CEO commented, “Second quarter revenue and\nadjusted EBITDA both exceeded consensus expectations, reflecting continued\nmargin expansion, disciplined execution, and resilience in our operating\nmodel. While year-over-year revenue declined and contracted revenue remains\nbelow prior-year levels, these trends are concentrated among a small number of\ncustomers, and we are encouraged by increased investment across other portions\nof our customer base. Our continued investment in platform capabilities,\nincluding recent product launches and expanded programmatic initiatives, is\nstrengthening customer engagement as we move into the 2027 planning cycle.\nDespite some variability in second-half timing and mix, our first-half\nperformance and commercial momentum give us confidence to reiterate full-year\n2026 guidance of $95 million to $100 million in revenue and $21 million to $25\nmillion in adjusted EBITDA. We also expanded the long-term opportunity for\nOptimizeRx through three platform advancements: DeepIntent became the first\nhealthcare demand-side platform (DSP) to integrate our authenticated\nelectronic health record (EHR) network, we launched our patent-pending Natural\nLanguage Audience Builder, and we introduced CopayCue, our next-generation\ncopay activation solution. These innovations strengthen our position in\nartificial intelligence (AI)-enabled audience intelligence, programmatic\npoint-of-care activation, and clinical workflow engagement while creating\nopportunities for recurring growth.\n\n“Finally, we continued to strengthen our balance sheet by paying down $5.3\nmillion of term loan principal during the quarter—$5.0 million ahead of\nschedule—and an additional $3.0 million subsequent to quarter-end. We\nbelieve our disciplined execution, expanding technology platform, improving\ncustomer engagement, and strong financial position leave us well positioned to\ncreate meaningful long-term shareholder value.”\n\n Rolling Twelve Months Ended \n June 30, \n Key Performance Indicators (KPIs)** 2026 2025 \n (in thousands, except percentages) \n Average revenue per top 20 pharmaceutical manufacturers $ 2,659 $ 3,095 \n Percent of total revenue attributable to top 20 pharmaceutical manufacturers 54 % 59 % \n Net revenue retention 90 % 121 % \n Revenue per average full-time employee $ 750 $ 767 \n \n\n2026 Financial Outlook\n\nThe Company is reiterating its fiscal year 2026 guidance, and expects revenue\nof $95 million to $100 million and adjusted EBITDA of $21 million to $25\nmillion.\n\nConference Call\n\n Date: Wednesday, August 12, 2026 \n Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) \n Toll Free: 1-877-407-9716 \n International: 1-201-493-6779 \n Conference ID: 13761843 \n Call Me : https://callme.viavid.com/viavid/?callme=true&passcode=13760191&h=true&info=company-email&r=true&B=6 \n Webcast : https://viavid.webcasts.com/starthere.jsp?ei=1770269&tp_key=7d483832d3 \n Webcast Replay : The archived webcast will be on the investor relations section of the OptimizeRx website. \n \n\nIndividual Meeting Invitation\n\nIn an effort to increase relations with institutional investors, OptimizeRx\nmanagement has dedicated time to hosting individual meetings with portfolio\nmanagers and analysts. If you are interested in scheduling a meeting with\nOptimizeRx management, please contact: adsilva@optimizerx.com or\ndfarrell@lifesciadvisors.com.\n\n*Non-GAAP Measures\n\nIn addition to the financial measures prepared in accordance with generally\naccepted accounting principles (GAAP), this earnings release also contains\nnon-GAAP financial measures. The reasons why we believe these measures provide\nuseful information to investors and, for historical periods, a reconciliation\nof these measures to the most directly comparable GAAP measures are included\nin the supplemental tables that follow.\n\nAlthough the Company provides guidance for adjusted EBITDA, a non-GAAP\nfinancial measure, it is not able to provide guidance to the most directly\ncomparable GAAP measure. Reconciliations for forward-looking figures would\nrequire unreasonable effort at this time because of the uncertainty and\nvariability of the nature and amount of certain components of various\nnecessary GAAP components, including, for example, those related to\ncompensation, acquisition expenses, other income, amortization or others that\nmay arise during the year, and the Company’s management believes such\nreconciliations would imply a degree of precision that would be confusing or\nmisleading to investors. For the same reasons, the Company is unable to\naddress the probable significance of the unavailable information.\n\n**Definition of Key Performance Indicators\n\nTop 20 pharmaceutical manufacturers: We have updated the definition of “top\n20 pharmaceutical manufacturers” in our key performance indicators to be\nbased upon Fierce Pharma’s most updated list of “The top 20 pharma\ncompanies by 2025 revenue”. We previously used “The top 20 pharma\ncompanies by 2024 revenue”. As a result of this change, prior periods have\nbeen restated for comparative purposes.\n\nNet revenue retention: Net revenue retention is a comparison of revenue\ngenerated from all clients in the previous period to total revenue generated\nfrom the same clients in the following year (i.e., excludes new client\nrelationships for the most recent year).\n\nRevenue per average full-time employee: We define revenue per average\nfull-time employee (FTE) as total revenue over the last 12 months (LTM)\ndivided by the average number of employees over the LTM, which is calculated\nby taking our total number of FTEs at the end of the prior year period by our\ntotal FTE headcount at the end of the most recent period.\n\nAbout OptimizeRx\n\nOptimizeRx is a leading healthcare technology company that’s redefining how\nlife science brands connect with patients and healthcare providers. Our\nplatform combines innovative AI-driven tools like the Dynamic Audience\nActivation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver\ntimely, relevant, and hyper-local engagement. By bridging the gap between HCP\nand direct-to-consumer (DTC) strategies, we empower brands to create\nsynchronized marketing solutions that drive faster treatment decisions and\nimproved patient outcomes.\n\nOur commitment to privacy-safe, patient-centric technology ensures that every\ninteraction is designed to make a meaningful impact, delivering life-changing\ntherapies to the right patients at the right time. Headquartered in Waltham,\nMassachusetts, OptimizeRx partners with some of the world’s leading\npharmaceutical and life sciences companies to transform the healthcare\nlandscape and create a healthier future for all.\n\nFor more information, follow the Company on X, LinkedIn or\nvisit www.optimizerx.com. \n\nImportant Cautions Regarding Forward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Words such as\n“anticipates”, “believes”, “estimates”, “expects”,\n“forecasts”, “intends”, “plans”, “projects”, “targets”,\n“designed”, “could”, “may”, “should”, “will” or other\nsimilar words and expressions are intended to identify these forward-looking\nstatements. All statements that reflect the Company’s expectations,\nassumptions, projections, beliefs or opinions about the future, other than\nstatements of historical fact, are forward-looking statements, including,\nwithout limitation, statements relating to the Company’s future performance,\nexpected revenues, expected adjusted EBITDA, AI-enabled audience intelligence,\nprogrammatic point-of-care activation, clinical workflow engagement creating\nopportunities for recurring growth, the Company's disciplined execution,\nexpanding technology platform, increased customer investment, and strong\nfinancial position leaving the Company to be well-positioned to create\nmeaningful long-term shareholder value, and other statements relating to\nfuture performance, plans, and expectations. These forward-looking statements\nare based on the Company’s current expectations and involve assumptions\nregarding the Company’s business, the economy, and other future conditions\nthat may never materialize or may prove to be incorrect. Forward-looking\nstatements are inherently subject to risks and uncertainties, some of which\ncannot be predicted, or quantified. Actual results and the timing of events\ncould differ materially from those anticipated in such forward-looking\nstatements as a result of various risks and uncertainties including, but not\nlimited to, the effect of government regulation, seasonal trends, dependence\non a concentrated group of customers, cybersecurity incidents that could\ndisrupt operations, the ability to keep pace with growing and evolving\ntechnology, the ability to maintain contracts with electronic prescription\nplatforms and electronic health records networks, competition, and other\nfactors discussed in the Company’s Annual Report on Form 10-K for the fiscal\nyear ended December 31, 2025, its subsequent Quarterly Reports on Form 10-Q,\nand in other filings the Company has made and may make with the Securities and\nExchange Commission in the future. One should not place undue reliance on\nthese forward-looking statements, which speak only as of the date on which\nthey were made. The Company undertakes no obligation to update such statements\nto reflect events that occur or circumstances that exist after the date on\nwhich they were made, except as may be required by law.\n\nOptimizeRx Contact\nAndy D’Silva, Chief Business Officer\nadsilva@optimizerx.com\n\nInvestor Relations Contact\nDouglas Farrell\nLifeSci Advisors, LLC\ndfarrell@lifesciadvisors.com\n\n OPTIMIZERX CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) \n \n June 30, December 31, \n 2026 2025 \n ASSETS (unaudited) \n Current assets \n Cash and cash equivalents $ 24,096 $ 23,365 \n Accounts receivable, net of allowance for credit losses of $260 and $260 at June 30, 2026 and December 31, 2025, respectively 24,796 37,752 \n Taxes receivable 2,328 752 \n Prepaid expenses and other 2,926 2,846 \n Total current assets 54,146 64,715 \n Property and equipment, net 122 106 \n Other assets \n Goodwill 70,869 70,869 \n Patent rights, net 4,267 4,586 \n Technology assets, net 6,281 6,870 \n Tradename and customer relationships, net 28,162 29,340 \n Operating lease right of use assets 452 404 \n Security deposits and other assets 18 28 \n Total other assets 110,049 112,097 \n TOTAL ASSETS $ 164,317 $ 176,918 \n \n LIABILITIES AND STOCKHOLDERS’ EQUITY \n Current liabilities \n Current portion of long-term debt $ 1,250 $ 4,255 \n Accounts payable 1,323 1,636 \n Accrued expenses 5,389 11,591 \n Revenue share payable 813 3,086 \n Current portion of lease liabilities 227 193 \n Deferred revenue 709 503 \n Total current liabilities 9,711 21,264 \n Non-current liabilities \n Long-term debt, net 17,757 21,421 \n Lease liabilities, net of current portion 246 234 \n Deferred tax liabilities, net 5,521 5,705 \n Total liabilities 33,235 48,624 \n Commitments and contingencies \n Stockholders’ equity \n Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding at June 30, 2026 or December 31, 2025 — — \n Common stock, $0.001 par value, 166,666,667 shares authorized, 20,574,233 and 20,500,986 shares issued at June 30, 2026 and December 31, 2025, respectively 21 20 \n Treasury stock, $0.001 par value, 1,741,397 shares held at June 30, 2026 and December 31, 2025. (2 ) (2 ) \n Additional paid-in-capital 211,486 207,512 \n Accumulated other comprehensive income (loss) 11 — \n Accumulated deficit (80,434 ) (79,236 ) \n Total stockholders’ equity 131,082 128,294 \n TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 164,317 $ 176,918 \n \n\n\n\n OPTIMIZERX CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) \n (in thousands, except share and per share data, unaudited) \n \n For the Three Months Ended For the Six Months Ended \n June 30, June 30, \n 2026 2025 2026 2025 \n \n Net revenue $ 20,504 $ 29,195 $ 40,348 $ 51,123 \n \n Expenses \n Cost of revenues, exclusive of depreciation and amortization presented separately below 4,816 10,560 9,728 19,144 \n Sales and marketing 5,528 5,865 10,257 10,850 \n General and administrative 3,702 3,909 7,215 8,466 \n Research and development 3,274 3,092 6,676 6,344 \n Stock-based compensation 2,208 1,488 4,036 3,046 \n Depreciation and amortization 1,064 1,074 2,128 2,168 \n Total expenses 20,592 25,988 40,040 50,018 \n Income from operations (88 ) 3,207 308 1,105 \n Other income (expense) \n Interest expense (1,127 ) (1,603 ) (2,282 ) (2,899 ) \n Other income 38 37 76 76 \n Interest income 81 90 158 177 \n Total other expenses, net (1,008 ) (1,476 ) (2,048 ) (2,646 ) \n Income (loss) before provision for income taxes (1,096 ) 1,731 (1,740 ) (1,541 ) \n Income tax benefit (expense) 393 (199 ) 542 874 \n Net income (loss) $ (703 ) $ 1,532 $ (1,198 ) $ (667 ) \n \n Other comprehensive income (loss), net of tax: \n Foreign currency translation adjustment 11 — 11 — \n Comprehensive income (loss) $ (692 ) $ 1,532 $ (1,187 ) $ (667 ) \n \n Weighted average number of shares outstanding – basic 18,785,596 18,510,834 18,773,638 18,490,931 \n Weighted average number of shares outstanding – diluted 18,785,596 19,015,496 18,773,638 18,490,931 \n Income (loss) per share – basic $ (0.04 ) $ 0.08 $ (0.06 ) $ (0.04 ) \n Income (loss) per share – diluted $ (0.04 ) $ 0.08 $ (0.06 ) $ (0.04 ) \n \n\n\n\n OPTIMIZERX CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands, unaudited) \n \n For the Six Months Ended June 30, \n 2026 2025 \n OPERATING ACTIVITIES: \n Net loss $ (1,198 ) $ (667 ) \n Adjustments to reconcile net loss to net cash provided by operating activities: \n Depreciation and amortization 2,128 2,168 \n Stock-based compensation 4,036 3,046 \n Amortization of debt issuance costs 635 611 \n Changes in: \n Accounts receivable 12,956 4,700 \n Prepaid expenses and other assets (81 ) (958 ) \n Accounts payable (313 ) (174 ) \n Revenue share payable (2,273 ) (2,462 ) \n Accrued expenses and other liabilities (6,190 ) 4,138 \n Operating lease liabilities (2 ) 9 \n Deferred tax liabilities (184 ) (1,033 ) \n Taxes receivable and payable (1,576 ) (964 ) \n Deferred revenue 206 11 \n NET CASH PROVIDED BY OPERATING ACTIVITIES 8,144 8,425 \n \n INVESTING ACTIVITIES: \n Purchase of property and equipment (56 ) (37 ) \n Capitalized software development costs — (91 ) \n NET CASH USED IN INVESTING ACTIVITIES (56 ) (128 ) \n \n FINANCING ACTIVITIES: \n Cash paid for employee withholding taxes related to the vesting of restricted stock units (63 ) (92 ) \n Proceeds from term loan, net of issuance costs 24,298 — \n Repayment of long-term debt (31,603 ) (5,000 ) \n NET CASH USED IN FINANCING ACTIVITIES (7,368 ) (5,092 ) \n EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH 11 \n EQUIVALENTS \n NET INCREASE IN CASH AND CASH EQUIVALENTS 731 3,205 \n CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD 23,365 13,380 \n CASH AND CASH EQUIVALENTS - END OF PERIOD $ 24,096 $ 16,585 \n \n SUPPLEMENTAL CASH FLOW INFORMATION: \n Cash paid for interest $ 1,566 $ 3,409 \n Cash paid for income taxes $ 1,223 $ 1,087 \n \n\nOPTIMIZERX CORPORATION\nRECONCILIATION of GAAP to NON-GAAP FINANCIAL MEASURES\n(in thousands, except share and per share data, unaudited)\n\nThis earnings release includes certain financial measures that are not\nprepared in accordance with generally accepted accounting principles (GAAP).\nThese non-GAAP financial measures are performance measures that are not\ndefined under GAAP and should be considered in addition to, and not as a\nsubstitute for, the most directly comparable GAAP measures. They may also not\nbe comparable to similarly titled measures reported by other companies.\nManagement believes that presenting these non-GAAP financial measures provides\nuseful supplemental information that facilitates comparison of the Company's\nhistorical operating results and trends, and offers transparency into how\nmanagement evaluates the business. Management uses these measures in making\nfinancial, operating and planning decisions and in evaluating the Company's\nperformance. Excluding items that management does not consider reflective of\nongoing operating results improves the comparability of year-over-year results\nand helps investors better understand the Company’s underlying performance.\nThese adjustments may include items such as asset impairment charges,\namortization, stock-based compensation, acquisition expenses, severance\nrelated to executive departures and reductions in force initiatives,\nshareholder activist related fees, CEO search fees, CMO search fees, other\nincome, estimated income tax impact from adjustments and other items that\nmanagement believes are not related to the Company’s ongoing performance.\n\n For the Three Months Ended June 30, For the Six Months Ended June 30, \n 2026 2025 2026 2025 \n Net income (loss) $ (703 ) $ 1,532 $ (1,198 ) $ (667 ) \n Depreciation and amortization 1,064 1,074 2,128 2,168 \n Stock-based compensation 2,208 1,488 4,036 3,046 \n Severance expenses 1,714 — 1,744 275 \n Shareholder activist related fees — — — 451 \n CEO search fees — — — 225 \n CMO search fees 40 — 40 — \n Other income (38 ) (37 ) (76 ) (76 ) \n Amortization of debt issuance costs 277 437 635 611 \n Estimated income tax impact from adjustments* (1,456 ) (819 ) (2,353 ) (1,853 ) \n Non-GAAP net income $ 3,106 $ 3,675 $ 4,956 $ 4,180 \n \n Non-GAAP net income per share \n Diluted $ 0.16 $ 0.19 $ 0.26 $ 0.22 \n Weighted average shares outstanding: \n Diluted 18,907,884 19,015,496 18,992,154 18,599,906 \n \n *Estimated income tax impact from adjustments - consists of current and deferred income tax expense commensurate with the level of adjusted income before income taxes and utilizes an estimated current, blended U.S. and state statutory annual tax rate of 27.6% for all fiscal periods of fiscal 2026 and fiscal 2025. This rate may be subject to change in the future, including as a result of changes in tax policy or tax strategy. \n \n\n\n\n For the Three Months Ended June 30, For the Six Months Ended June 30, \n 2026 2025 2026 2025 \n Net income (loss) $ (703 ) $ 1,532 $ (1,198 ) $ (667 ) \n Depreciation and amortization 1,064 1,074 2,128 2,168 \n Income tax (benefit) expense (393 ) 199 (542 ) (874 ) \n Stock-based compensation 2,208 1,488 4,036 3,046 \n Severance expenses 1,714 — 1,744 275 \n Shareholder activist related fees — — — 451 \n CEO search fees — — — 225 \n CMO search fees 40 — 40 — \n Other income (38 ) (37 ) (76 ) (76 ) \n Interest expense, net 1,046 1,513 2,124 2,722 \n Adjusted EBITDA $ 4,938 $ 5,769 $ 8,256 $ 7,270 \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/a0504bf7-72fc-4cd4-8489-a207313dbabd)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-12T20:01:00.855295258Z","server_sent_at_ms":1786564860855},"received_at":"2026-08-12T20:01:00.907Z","source_url":"https://www.globenewswire.com/news-release/2026/08/12/3344034/0/en/optimizerx-reports-second-quarter-2026-financial-results-and-updates-fiscal-year-2026-guidance.html"},"analysis":{"id":"106150","press_release_id":"117160","analysis_json":{"industry":{"label":"Health Care Technology","sector":"Health Care"},"redFlags":["Revenue decreased 30% year-over-year","Net revenue retention dropped to 90% from 121%","GAAP net loss of $(0.7) million compared to net income of $1.5 million in prior year"],"eventType":"earnings","narrative":"OptimizeRx reported Q2 revenue of $20.5 million, a 30% decrease year-over-year, though adjusted EBITDA of $4.9 million exceeded consensus expectations.\n\nManagement reaffirmed its fiscal year 2026 guidance for revenue of $95 million to $100 million and adjusted EBITDA of $21 million to $25 million.\n\nThe company strengthened its balance sheet by repaying $5.3 million of term loan principal during the quarter and an additional $3.0 million subsequent to quarter-end.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Earnings beat supports guidance despite significant top-line contraction and retention deterioration."},"keyFigures":{"revenue":20500000,"guidance":"FY2026 revenue $95M-$100M, adjusted EBITDA $21M-$25M","revenueYoy":"-30%","customDimensions":{"cash":24100000,"adjusted_eps":0.16,"adjusted_ebitda":4900000,"net_revenue_retention":"90%"}},"quotedText":"Second quarter revenue and adjusted EBITDA both exceeded consensus expectations, reflecting continued margin expansion, disciplined execution, and resilience in our operating model.","namedEntities":{"people":[{"name":"Stephen L. Silvestro","role":"CEO"}],"products":["DeepIntent","Natural Language Audience Builder","CopayCue","Dynamic Audience Activation Platform","Micro-Neighborhood Targeting"],"companies":[{"name":"OptimizeRx Corp.","ticker":"OPRX"},{"name":"DeepIntent","relationship":"partner"}],"dollarAmounts":[{"amount":"$20.5 million","context":"Q2 2026 revenue"},{"amount":"$29.2 million","context":"Q2 2025 revenue"},{"amount":"$(0.7) million","context":"Q2 2026 net loss"},{"amount":"$4.9 million","context":"Q2 2026 adjusted EBITDA"},{"amount":"$95 - $100 million","context":"FY2026 revenue guidance"},{"amount":"$21 - $25 million","context":"FY2026 adjusted EBITDA guidance"},{"amount":"$35 million","context":"traditional banking facility"},{"amount":"$5.3 million","context":"term loan principal repaid during quarter"},{"amount":"$3.0 million","context":"term loan principal repaid subsequent to quarter-end"}]},"materialImpact":{"score":3,"reasoning":"Q2 revenue and adjusted EBITDA exceeded consensus expectations, supporting the reaffirmation of full-year guidance despite a significant 30% year-over-year revenue decline."},"tickerRelevance":{"others":[],"primary":"OPRX"},"globalImportance":25,"audienceRelevance":20,"eventTypeSecondary":["guidance_update"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"earnings-beat-reaffirmation","sectorWeight":"healthcare-tech"}},"event_type":"earnings","event_type_secondary":["guidance_update"],"sentiment":"bullish","material_impact_score":3,"narrative":"OptimizeRx reported Q2 revenue of $20.5 million, a 30% decrease year-over-year, though adjusted EBITDA of $4.9 million exceeded consensus expectations.\n\nManagement reaffirmed its fiscal year 2026 guidance for revenue of $95 million to $100 million and adjusted EBITDA of $21 million to $25 million.\n\nThe company strengthened its balance sheet by repaying $5.3 million of term loan principal during the quarter and an additional $3.0 million subsequent to quarter-end.","key_figures":{"revenue":20500000,"guidance":"FY2026 revenue $95M-$100M, adjusted EBITDA $21M-$25M","revenueYoy":"-30%","customDimensions":{"cash":24100000,"adjusted_eps":0.16,"adjusted_ebitda":4900000,"net_revenue_retention":"90%"}},"named_entities":{"people":[{"name":"Stephen L. Silvestro","role":"CEO"}],"products":["DeepIntent","Natural Language Audience Builder","CopayCue","Dynamic Audience Activation Platform","Micro-Neighborhood Targeting"],"companies":[{"name":"OptimizeRx Corp.","ticker":"OPRX"},{"name":"DeepIntent","relationship":"partner"}],"dollarAmounts":[{"amount":"$20.5 million","context":"Q2 2026 revenue"},{"amount":"$29.2 million","context":"Q2 2025 revenue"},{"amount":"$(0.7) million","context":"Q2 2026 net loss"},{"amount":"$4.9 million","context":"Q2 2026 adjusted EBITDA"},{"amount":"$95 - $100 million","context":"FY2026 revenue guidance"},{"amount":"$21 - $25 million","context":"FY2026 adjusted EBITDA guidance"},{"amount":"$35 million","context":"traditional banking facility"},{"amount":"$5.3 million","context":"term loan principal repaid during quarter"},{"amount":"$3.0 million","context":"term loan principal repaid subsequent to quarter-end"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-12T20:22:20.101Z","global_importance":25,"audience_relevance":20,"importance_components":{"tickerTier":"small-cap","eventGravity":"earnings-beat-reaffirmation","sectorWeight":"healthcare-tech"}},"durationMs":218018,"modelName":"glm-4.7"}}